首页> 外文OA文献 >Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

【2h】

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

机译：后续疗法对FIRE-3 / aIO KRK0306试验结果的影响：FOLFIRI加西妥昔单抗或贝伐单抗治疗转移性结直肠癌KRas野生型肿瘤患者的一线治疗

页面导航

著录项
相似文献
相关主题

著录项

作者
Dominik P. Modest; Sebastian Stintzing; Ludwig Fischer Von Weikersthal; Thomas Decker; Er Kiani; Ursula Vehling-kaiser; Salah-eddin Al-batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Svantje Held; Markus Möhler; Andreas Jung; Thomas Kirchner; Volker Heinemann;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer [J] . Modest Dominik P., Stintzing Sebastian, von Weikersthal Ludwig Fischer, Journal of Clinical Oncology . 2015,第32期

机译：后续治疗对FIRE-3 / AIO KRK0306试验结果的影响：FOLFIRI加西妥昔单抗或贝伐单抗一线治疗转移性结直肠癌KRAS野生型肿瘤患者
2. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro) [J] . Michl M., Stintzing S., Fischer von Weikersthal L., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第8期

机译：在接受一线FOLFIRI加西妥昔单抗或贝伐单抗治疗的KRAS外显子2野生型和扩展RAS野生型转移性结直肠癌患者中，CEA反应与肿瘤反应和生存相关（FIRE-3试验）（aEuro）
3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial [J] . The lancet oncology . 2014,第10期

机译：FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌（FIRE-3）患者的一线治疗：一项随机，开放标签的3期临床试验
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials [O] . M D Berger, S Stintzing, V Heinemann, -1

机译：一线FOLFIRI和贝伐单抗治疗转移性结直肠癌患者MAPK信号通路的遗传变异对结局的影响：FIRE-3和TRIBE试验数据
7. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials [O] . M.D. Berger, S. Stintzing, V. Heinemann, 2017

机译：MAPK信号传导途径遗传变异对初级Folfiri和Bevacizumab治疗的转移结直肠癌患者的结果：来自Fire-3和Tribe试验的数据

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

著录项

相似文献

相关主题

期刊订阅